Header: A large group of employers sues United Healthcare, asserting it overpays providers when it is merely dolely out third-party administrator payments (the employer's money.) They say it is more careful when it is acting as an insurer and paying its own money. ?Could this show up as high-end payments for lab tests (e.g. $200 for $10 test) in PAMA data?
###
- See Benefits Digest [open] here.
- See Beckers [open] here.
- See Insurance Newsnet [open] here.
- See Bloomberg Law [firewall] here.
- See Law360 [firewall] here.
- Find the case, Eastern District Texas, 62pp, here.
- Aramark Services, Inc., et al. v. United Health Group Incorporated, et al.
- 2:26-cv-009490JRG
- Filed on October 20, 2026, redacted. [PDF link via Benefits Digest]
 |
| click to enlarge |
In a cartoon example above, a test has one PAMA payment at $50, 10 at $100, one at $500, and COGS is $50. The ten tests contribute $500 margin, the one high test contributes $450 margin just by itself.
###
AI Corner: Chat GPT 6
###
1 From payment distributions to laboratory economics
What a median cannot show
Bruce Quinn’s recent PAMA analysis illustrates the starting point.
Distributions of reported private-payer rates for selected laboratory codes
show patterns that a single average or median cannot communicate. Some rates
cluster tightly; others are widely dispersed or have multiple concentrations. A
billing code is a useful unit of comparison, although it does not always
identify an identical assay, service configuration, or contractual setting.
The next analytical step is to distinguish three quantities:
the number of tests at each price, the total dollars associated with those
tests, and their contribution after an explicit cost assumption. In PAMA
reporting, a data row can represent a rate and an associated volume. Counting
rows therefore does not necessarily count tests. The calculations should use
each exact reported rate multiplied by its reported volume, then aggregate
those amounts into display bins. CMS also includes applicable patient cost
sharing in reported private-payer rates, so those dollars should not
automatically be described as payments made entirely by insurers. CMS reporting guidance
How a small number of claims can drive contribution
Consider an intentionally simple example: one test is paid
at $50, ten at $100, and one at $500. Assume a median payment of $100 and a
cost of $50 for each test. The twelve tests generate $1,550 in payments and
$950 after subtracting the assumed $600 cost. The single $500 payment
represents 8.3% of test volume, 32.3% of
payments, and 47.4% of contribution after assumed cost.
If that one payment fell from $500 to $100, total
contribution would fall from $950 to $550, a decline of 42.1%, with no change
in test volume or assumed cost. A payment below $50 would make a negative
contribution in this model. These are illustrative calculations, not estimates
of any laboratory’s actual margins. Contribution here means payment less the
stated cost assumption, before overhead; it is not net profit or net cash flow.
 |
| click to enlarge |
The same calculation can be performed on hundreds of exact dollar-and-cent rates without replacing them with bin midpoints. An open-ended category such as “more than $1,000” presents no difficulty when the underlying prices remain available. But a national distribution cannot establish which laboratory receives the high payments, what its costs are, or why those rates exist. A high-price tail identifies a question for investigation; it does not establish an overpayment.
2 Employers challenge UnitedHealth
TPA versus insurer and who bears the risk
The employer dispute brings that question into a different
setting. A third-party administrator, or
TPA, administers a health plan: it processes claims, applies coverage and
payment rules, and arranges payments. In a self-funded employer plan, the
employer or plan bears the covered claim costs. In a fully insured arrangement,
an insurer receives premiums and bears the contractual financial risk of
covered claims. The same corporate group can serve as a TPA for some
employers and as an insurer for others. The distinction concerns its role in
the particular arrangement.
The case and the parties
That distinction is central to Aramark Services, Inc., et al. v. United Health Group Incorporated, et
al., No. 2:26-cv-00949-JRG, in
the Eastern District of Texas, Marshall Division. The 62-page redacted complaint, filed as Document
3 on October 20, 2026, brings together Aramark, Whirlpool, W.W. Grainger, Kraft
Heinz, Ralph Lauren, and Sterling Jewelers, along with associated plans and
benefit committees. Defendants include UnitedHealth entities, Healthscope Benefits,
and United Medical Resources, commonly known as UMR.
The plaintiffs allege that United administered their
self-funded plans, improperly approved claims, extracted undisclosed
compensation, and obstructed oversight. They say the resulting losses amount to
millions of dollars. These are allegations in a complaint, not judicial
findings. United disputes them; in a statement reported by InsuranceNewsNet, the company said, “We
strongly disagree with these allegations and intend to vigorously defend
against them.” Many contractual passages and transaction amounts are redacted,
which limits independent evaluation of the public pleading.
3 Inside the complaint
Alleged payment errors and inadequate review
The complaint describes specific alleged failures beyond a
general objection to high medical prices. It alleges payments for claims with
missing or invalid billing information, high-value claims paid without
supporting medical-record review, and services excluded under the particular
plans. It also describes inconsistent claims that would require comparison
across related bills. One example concerns infusion services allegedly paid
twice for the same member and date, under different claim identifiers, without
evidence of a separate infusion. The dollar amount of that example is redacted.
(Complaint, paragraphs 62–72, pages 22–25.)
The pricing allegations are particularly relevant to the
distribution analysis. The employers say that even the limited data available
revealed hundreds of payments exceeding
the provider’s billed amount and thousands of claims paid at allegedly
excessive rates. They compare payments with amounts the provider ordinarily
received, commercial network prices, and Medicare rates. Those comparisons are
investigative benchmarks; a payment above Medicare or above a statistical
median does not, by itself, establish a contractual violation. The applicable
coverage rules, contract, coding, and circumstances still matter. (Paragraphs
73–75, page 26.)
The employers also allege that United applied less scrutiny
when spending self-funded plan assets than when paying claims for its own fully
insured business. They describe extensive automated adjudication with little
meaningful human review. Automation itself is not the legal issue. The
allegation concerns whether the administrator used adequate controls and
fulfilled its obligations when approving payments with plan money. (Paragraph
40, page 15; paragraphs 107–109, pages 38–39.)
Another striking allegation concerns what the complaint
calls provider “exclusion lists.” In this context, the term means exclusion
from some claims scrutiny. The employers contend that United offered certain
providers little or limited review as an inducement to join its network,
without informing the employer clients. The complaint expressly says discovery
will establish the use of these arrangements. That wording matters: the
allegation is presented partly as something the plaintiffs expect to substantiate
through litigation. (Paragraphs 110–112, pages 39–40.)
What the complaint says about laboratories and genomics
Laboratory providers
are mentioned, but the public complaint does not present a laboratory or
genomics case study. Paragraph 82, on page 29, includes laboratory service
providers among the healthcare businesses United allegedly owns through
affiliates. The next paragraph alleges that the plans paid United-owned
providers unjustifiably high rates compared with independent providers. The
plaintiffs acknowledge that restricted data access has prevented a robust
comparative analysis. The public text does not identify a particular laboratory
test, genomic assay, sequencing service, or PAMA payment distribution as evidence.
Its laboratory relevance is therefore both explicit, through the reference to
laboratory providers, and analytical, through the broader questions about
payment and ownership incentives.
Cross-plan offsetting and who receives the recovery
The complaint’s treatment of cross-plan offsetting explains why following the money matters. Its
example begins with a doctor receiving $1,000 from an employer plan for a
service later determined to warrant $600. United allegedly recovers the $400
difference by reducing a subsequent payment to the same doctor for a patient in
a United fully insured plan. Instead of paying the doctor $600 on that second
claim, United pays $200. According to the example, the original employer plan
receives no $400 credit; United’s insured business benefits from the reduced payment.
This is the complaint’s explanatory illustration, not a separately established
transaction. (Paragraphs 85–92, pages 30–33.)
The issue is which plan receives the benefit of a recovery.
The complaint invokes Peterson v.
UnitedHealth Group, a 2019 Eighth Circuit decision. That court
rejected United’s interpretation of the plan language at issue as authorizing
cross-plan offsetting and discussed the fiduciary concerns it creates. It did
not decide that every possible cross-plan offset violates ERISA. The present
employers challenge both the handling of their money and the adequacy of
contractual authorization and disclosure.
Repricing fees and the meaning of savings
The allegations about out-of-network
repricing and “shared savings” fees add a further complication. The
plaintiffs say United used repricing vendors, including MultiPlan, to negotiate
provider payments and charged fees calculated from the difference between a
provider’s billed charge and the amount ultimately paid. They argue that the
billed charge could substantially exceed what the plan was ever obligated to
pay, making the claimed savings an inflated basis for compensation. Some plan
provisions, they say, already limited benefits using Medicare-based or other
benchmarks. (Paragraphs 93–102, pages 33–36.)
The employers further allege that these fees sometimes
exceeded the provider’s payment and were concealed within claim-funding
requests or disclosed only in aggregate. This aspect of the case is especially
relevant to interpretation of laboratory data: the employer’s total expense, the laboratory’s receipts, and the
administrator’s compensation are different quantities. An employer could
allegedly spend too much even while a provider was paid relatively little. A
chart of laboratory payment rates cannot reveal all the fees or transfers
between the plan and its administrator.
Access to payment records and meaningful audits
The demand for underlying data consequently runs through the
complaint. The employers seek the records needed to reconcile what providers
submitted, what the administrator approved, what the plans funded, and what
providers received. They discuss electronic claim submissions, known as 837
transactions, and electronic remittance advice, known as 835 transactions.
Remittance records contain payment and adjustment information needed to
understand the disposition of claims. The plaintiffs allege that some employers
received only partial data and others received incomplete, unusable, or
inaccessible information. (Paragraphs 45–60, pages 16–22.)
Audit design matters as well. The complaint challenges
restrictions on claim sampling and extrapolation and argues that checking a few
hundred claims cannot reliably detect problems requiring comparison across the
entire claim population. For example, examining one infusion bill alone may
miss its alleged duplicate under a different claim number. The employers also
allege that movement of funds through United-controlled accounts made it
difficult to reconcile amounts collected from plans with amounts paid to
providers. (Paragraphs 103–105, pages 36–37; paragraphs 117–120, pages 41–42.)
4 Legal stakes and implications for laboratories
Fiduciary duties and the claims under ERISA
The legal architecture explains why the case reaches beyond
an ordinary dispute over service quality. The plaintiffs contend that United
was a fiduciary under the Employee
Retirement Income Security Act, or ERISA, a role carrying duties of loyalty
and prudence toward the plans and their participants. They offer three grounds:
contractual fiduciary designations, discretionary authority over benefit and
payment decisions, and control over plan assets. Whether an administrator acted
as a fiduciary for the particular conduct challenged is an important legal
question; the label TPA alone does not resolve it. (Paragraphs 29–44, pages
10–16.)
The first five counts invoke ERISA duties, prohibited
transactions, and compensation disclosure requirements. A
prohibited-transaction theory asks whether plan assets were used in a
conflicted transaction, such as self-dealing or an impermissible transfer
benefiting a related party. That is a different inquiry from whether an
isolated bill was carelessly processed. The remaining counts include contract,
declaratory-relief, good-faith, alternative common-law fiduciary, negligence,
gross-negligence, and unjust-enrichment claims. These are alternative legal
routes pleaded by the employers, not twelve violations established by a court.
(Pages 44–60.)
The scope of compensation disclosure
One disclosure theory relies on ERISA section 408(b)(2)(B),
added by the Consolidated Appropriations Act, 2021. Its scope deserves
precision: Department of Labor guidance describes
requirements for covered brokerage or consulting services, subject to the
statute’s conditions. It should not be paraphrased as an automatic disclosure
rule for every TPA arrangement. How the challenged services and compensation
fit the provision is part of the legal inquiry. (Complaint, paragraphs 121–126,
pages 42–44; Count V, pages 49–51.)
What the employers want the court to order
The requested remedies are extensive. The employers seek
reimbursement of losses, disgorgement of profits, attorneys’ fees, and orders
providing access to claims data with privacy protections. They specifically ask
for employer, plan-sponsor, or trust identification and taxpayer identification
numbers on relevant 835 remittances, including those sent through
clearinghouses such as Change Healthcare. They also request punitive damages.
These are requests for relief; the complaint does not establish that each
remedy is available or will be awarded. (Pages 60–61.)
What laboratory executives can examine now
For laboratory businesses, the immediate research
opportunity is to measure dependence on unusually high payments accurately. A
volume-weighted distribution can show how often those payments occur.
Dollar-weighted calculations can show their revenue importance. Explicit,
test-specific cost assumptions can estimate their contribution, preferably
across several plausible cost scenarios. Those calculations should preserve the
underlying rates and volumes and distinguish a national dataset from the
experience of an individual laboratory.
The UnitedHealth lawsuit supplies a reason to ask the next
question: what supports the payments on which that contribution depends? They
may reflect valid contracts, differences in services, or other legitimate
circumstances. The employers allege that some medical payments instead reflect
deficient review, conflicts, or undisclosed arrangements. The public complaint
does not connect those allegations to particular PAMA outliers. It does show
why access to detailed payment records matters to both sides of the
transaction: the employer trying to account for its spending and the laboratory
trying to understand the durability of its revenue.
Source note:
Case analysis is based on the public, redacted complaint filed October 20,
2026, Document 3, with paragraph and page references supplied above. It
describes the pleading rather than a judicial determination of liability.
